Articles related to CAR T-CELL THERAPIES

Researchers reported the finding—the longest known CLL remission after CAR T-cell therapy—in Nature. The patients received an infusion of genetically engineered autologous T cells as part of a phase 1 clinical trial in 2010.

Matthew Lunning, DO, Associate Vice Chair of Research at the University of Nebraska Medical Center, reviews treatment implications of emerging research in CAR T-cell therapy for a variety of lymphomas subtypes, and discusses newer study outcomes, limitations to current CAR-T cell products, the state of allogenic CAR-T cell therapy, and key elements to consider when selecting therapy for a given patient.

Double-hit lymphoma presents as both aggressive, systematic disease with extra-nodal involvement and, apparently, as low-stage, less clinically aggressive disease. Since R-CHOP is much less effective in double-hit lymphoma, options such as CAR-T as well as novel drugs targeting cell-surface markers are being investigated. This interview with Dr. Ann S. LaCasce of Dana Farber summarizes current understanding and approaches to double-hit lymphoma.

Adults with confirmed R/R aNHL within 12 months after first-line (1L) chemo-immunotherapy were eligible for the randomized Phase III study, which demonstrated that tisagenlecleucel (tisa-cel) as second-line (2L) treatment in R/R aNHL patients did not have a higher event-free survival (EFS) vs. the standard-of-care (SOC). Read this late-breaking abstract from the ASH Annual Meeting & Exhibition to discover the contributing factors leading to the results, as well as how insights from this study will inform use of cellular treatment in the 2L R/R aNHL setting and the design of future CAR-T trials.

Clinical Advances in Hematology & Oncology talks with Sonali M. Smith, MD, an Elwood V. Jensen Professor in Medicine and Chief, Section of Hematology/Oncology at the University of Chicago, about all things transformed lymphoma, including risk factors, distinguishing characteristics, pathogenesis, traditional treatment approaches, treatment goals, new treatment strategies, and other promising areas of research.

In this series from Blood that tackles four cases studies, the outcomes of AML pediatric patients compared to children with ALL is explored, focusing on the emerging new treatments venetoclax (Venclexta; AbbVie/Genentech), CD33- and CD123-directed CAR T-cell therapy, CD123-directed antibody therapy, and menin inhibitors.